Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

August 14, 2018

First Patient Dosed in Phase 2 Trial of ADCT-402 in DLBCL

News

ADC Therapeutics has dosed the first participant in its Phase 2 trial assessing ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial is expected to support the ... Read more

August 2, 2018

Venclexta Triple Combo in NHL Patients Produces Long-lasting Responses in Phase 1 Trial

News

A combination of Venclexta (venetoclax), bendamustine, and Rituxan (rituximab) is tolerable and produces long-lasting responses in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), according to a Phase 1 trial. The study, “Venetoclax, bendamustine, ... Read more

July 19, 2018

Study Examines Prescription Rates for Rituximab Biosimilars in European NHL Patients

News

European patients with non-Hodgkin’s lymphoma (NHL) are more likely to receive rituximab biosimilars if they are fitter, have indolent disease, or follicular lymphoma, according to a new study. The study, “Treatment approach for ... Read more

June 25, 2018December 6, 2018

Kymriah Ellicits Prolonged Complete Responses in Advanced DLBCL Patients, Trial Data Show

News

Kymriah (tisagenlecleucel), a chimeric antigen receptor (CAR) T-cell therapy developed by Novartis, is able to ellicit prolonged complete responses with minor side effects in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according ... Read more

June 22, 2018

Duvelisib Effective in Relapsed or Refractory CLL/SLL Patients Who Failed Arzerra, Extension Study Shows

News

Patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who failed prior Arzerra (ofatumumab) treatment achieved robust and durable responses after switching to duvelisib, Verastem Oncology announced. Results from the Phase 3 crossover extension study IPI-145-12 (NCT02049515) ... Read more

June 11, 2018

First-line GEM-P Chemo Fails to Improve Response Rates in Peripheral T-cell Lymphomas, Results Show

News

The GEM-P chemotherapy regimen composed of gemcitabine, Platinol (cisplatin), and the corticosteroid methylprednisolone failed to improve response rates of peripheral T-cell lymphoma patients who have not received prior treatment, according to Phase 2 trial results. ... Read more

June 7, 2018

Cerdulatinib Shows Promising Phase 2a Trial Results in Blood Cancer Patients, Including NHL

News

Portola Pharmaceuticals‘ investigative therapy cerdulatinib is effective and well-tolerated in patients with several types of blood cancer, including non-Hodgkin’s lymphoma, who failed multiple prior therapies, according to interim results of ... Read more